This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Today, Senator Brian Schatz (D-HI) and Representative Barbara Lee (D-CA) introduced legislation, The Veterans Medical Marijuana Safe Harbor Act , to expand and facilitate medical cannabis access to military veterans suffering from chronic pain, PTSD, and other serious medical conditions. A copy of the bill is available here.
Steve Sisolak has signed legislation, Senate Bill 430 , expanding the pool of patients eligible for medical cannabis therapy. An estimated 18,000 Nevadans are registered with the state to access medical cannabis products. For more information on pending legislation, visit NORML’s ‘Take Action Center.’
” Furthermore, pain patients enrolled in medical cannabis access programs typically report decreasing or even eliminating their use of opiates after initiating cannabis therapy. percent in 2016).” ” Public comments “are part of the public record and are subject to public disclosure.
Doug Burgum signed legislation on Wednesday amending and expanding the state’s nascent medical cannabis access program. Though approved by voters in November 2016, the state’s medical cannabis access program is not yet fully operational. Republican Gov.
.” The findings are consistent with those of prior studies — such as those here , here , and here — which report that pain patients reduce their use of opioids following access to medical cannabis therapy.
House and Senate lawmakers have approved legislation, House File 732 , to expand the state’s medical cannabis access program. About 1,000 Iowans are currently authorized to access low-THC cannabis oils. About 1,000 Iowans are currently authorized to access low-THC cannabis oils. Kim Reynolds.
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. We are excited to explore the potential of emergent psychedelic therapies. Caution Regarding Forward-Looking Information. ABOUT WAKE NETWORK, INC.
Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. It is expected to be worth USD 2.1 About Zambon Spa.
With clinical research developing rapidly in Israel and with the use of innovative technology we hope to have this information in the near future. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy.
Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once certain financial milestones are met. Interested prospective funders can submit their contact information here.
A master distribution agreement has been signed with My Green Planet, a leading global agricultural supply group, giving Sporeo access to approximately 7,000 retailers across North America, Australia, and Europe. Levitee Labs aims to catalyze access to compounds and alternative medicines that enhances the wellbeing of society.
“The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.
Cannabis nurses are crucial in bridging the gap between traditional healthcare and emerging cannabis therapies. For example, teaching patients about the endocannabinoid system, terpenes, various cannabinoids, and consumption methods empowers them to make informed decisions catering to their unique health concerns.
Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61
Disease-modifying therapies (DMTs) are essential in altering the immune response to reduce inflammation and prevent further damage to the nervous system. Additionally, no current treatments can reverse existing neurological damage, highlighting the need for ongoing research into more effective therapies and potential cures.
We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. MAPS PBC strives to establish a supportive, equitable, and accessible work environment. European Regulatory Lead Executive Summary. Position Requirements.
In this ultimate guide to medical marijuana for chronic pain relief, we delve into the diverse world of medical cannabis strains and delivery methods specifically tailored to address chronic pain and provide valuable information on obtaining a medical cannabis card. To access medical cannabis for chronic pain management: 1.
Examples of common anxiety treatments include: Cognitive Behavioural Therapy (CBT) Reading Meditation Talk therapy Physical exercise. CBD has been shown to be very effective in multiple therapies, offering comfort to many people suffering from anxiety. How can I access CBD? Featured image by Joice Kelly on Unsplash.
That’s just one step being taken to prepare the state for the eventual implementation of Measure 109, in which 56 percent of voters approved last fall to legalize psychedelic mushroom therapy. . The post This New BIPOC-Run Group Is Educating People About Legal Mushroom Therapy in Oregon appeared first on SpeedWeed.
(TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce that following discussions with the U.K. The ILAP accelerates time to market and facilitates patient access to emerging and novel treatments.
The UK’s first and highest-rated medical cannabis clinic, Sapphire Medical Clinics , has today announced that it is reducing the cost of its consultations and appointments for patients enrolled through the Sapphire Access Scheme. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.
Pouya Farmand, CEO of Levitee, states: “We are thrilled to have acquired these five addiction clinics, which directly interface with patients that need alternative medicines and therapies the most. Further information about the Company is available on its website at? Recovery is the focus of ACT Medical’s policies and practices.
CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (“ Field Trip “), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has received conditional approval to list its common shares and warrants on the Toronto Stock Exchange (TSX). Cautionary Note Regarding Forward-Looking Information.
In fact, from pediatricians to geriatricians, I cannot think of any medical practitioner that does not need to be well informed about the endocannabinoid system and cannabis-based therapeutics. Who monitors their health and the long-term effects of the marijuana therapy?
Traditional treatments for these conditions often involve medication, physical therapy, or more invasive interventions like surgery. Refractory pain refers to pain resistant to traditional treatment approaches such as medication, physical therapy, or surgery. However, these approaches are not always practical for everyone.
It makes cannabis therapy an option that would help a range of patients who suffer from several medical conditions, thanks to the modulation of the endocannabinoid system (ECS). Overall, by targeting the ECS, cannabis therapy offers a holistic approach to symptom relief for various medical conditions.
The study found that 58% of physicians agree that “medical cannabis was a legitimate medical therapy.” ” The study concludes: “Providers generally believe that medical cannabis is a legitimate medical therapy. Healthcare providers play a critical role in facilitating patient access to medical cannabis.
Among other questions, the poll asked: To what extent would you support or oppose the government relaxing restrictions on research into the medical use of magic mushroom-based treatments (psilocybin- assisted therapies) for mental health conditions if this didn’t affect how it was classified in criminal law (e.g. as a class A drug)?
Veriheal does not support illegally consuming alternative therapeutic substances but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. Always consult a physician before attempting psychedelic therapy. A Magical Future.
The feds are looking for information on how cannabis and/or Kratom might treat pain. The AHRQ is hoping to gather information on four specific questions in particular. Medicinal cannabinoid therapies are saving and changing lives for people across America and around the world.
These products have not been shown to be safe or effective, and deceptive marketing of unproven treatments may keep some patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.”. What specific risks should consumers be informed about? Specifically, the agency fears that.
By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Promoting Research and Innovation The medical marijuana industry promotes research and innovation in the field of cannabis-based therapies.
Founded in 2019, Roots to Thrive is Canada’s first and only multidisciplinary, non-profit healthcare practice to legally offer evidence-informed, multi-week group therapy programs that include psilocybin-assisted and ketamine-assisted group therapy sessions.
My knowledge of Epigenetics has has since crossed over another area of passion: medical cannabis therapy. Of course, unique varieties of cannabis exert varying effects on individuals, an issue that may be solved through a new process that allows for genetic individualization of cannabis therapy.
Each type of insomnia may require different treatment approaches, including behavioral therapy, medication, lifestyle changes, or addressing underlying medical or psychological issues. For more information about the products and strains that work best for insomnia, read our A Guide to the Most Popular MMJ Strains.
June 18, 2021 (Chicago) — Palo Santo , the leading psychedelic investment fund helping to increase the supply of clinically effective and accessible mental health and addiction treatment solutions, issued the following statement regarding atai Life Sciences ’ (“atai” or “Company”) ( NASDAQ: ATAI ) initial public offering.
Any sales of psychedelic compounds would still be strictly prohibited; however, the initiative would allow for people to offer psychedelic services such as guidance and therapy or for harm reduction or spiritual purposes with or without payment. Not all alternative medicine advocates are in support of the Natural Medicine Health Act, however.
However, there has been growing interest in alternative therapies, including medical marijuana to treat glaucoma. This creates challenges for patients and healthcare providers in accessing and prescribing cannabis. Need more information about medical marijuana as a treatment? Take a look at our blog !
Setting aside for a minute how effective psychedelics may or may not be as breakthrough treatments for PTSD , there’s no doubt that cannabis is still much easier for most patients to access.
Governor Jay Inslee (D) of Washington signed legislation into law allowing medical cannabis to be accessed by patients on school grounds, and separate legislation allowing the production of industrial hemp in accordance with new federal hemp regulations. Click here to email your lawmakers in support of medical cannabis access.
Their study was approved by the Swedish Ethical Board and the researchers obtained informed consent from every participant. The researchers found that psychedelic users were more likely to have lower Evidence Integration Impairment scores—which assessed one’s “lack of ability to modify beliefs when facing new information.”
Recent Research Highlights: Journal of Clinical Medicine – “ Cannabinoid Therapy in Autoimmune Disorders “: A 2023 study examining the role of CB2 receptors in immune regulation showed promising results for conditions like rheumatoid arthritis and lupus.
The diversified venture fund is focused on tackling the growing global mental health crisis by investing in innovative psychedelic-based and adjacent therapies that are poised to shape the future of psychiatry and fields beyond. Innovative psychedelic-based and adjacent therapies are poised to shape the future of psychiatry and fields beyond.
Naropa University in Boulder, Colorado, has created an exciting new initiative for students: a minor in psychedelic studies, designed to train those who want to practice psychedelic-assisted therapy and other related careers. It’s tailored for students interested in exploring past and contemporary uses of psychedelics.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content